{
    "clinical_study": {
        "@rank": "156323", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Immulina 200 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "10 participants will be randomized to take 200 mg/day of Immulina."
            }, 
            {
                "arm_group_label": "Immulina 400 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "10 participants will be randomized to take 400 mg/day of Immulina."
            }, 
            {
                "arm_group_label": "Immulina 800 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "10 participants will be randomized to take 800 mg/day of Immulina."
            }
        ], 
        "brief_summary": {
            "textblock": "This will be a small study aimed at determining the effects of oral Immulina consumption on\n      the immune system in elderly individuals."
        }, 
        "brief_title": "Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals", 
        "condition": "Elderly Immune Senescence", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 60 and older;\n\n          -  Generally otherwise healthy for age and not taking medications/supplements that could\n             be expected to affect stress responses and/or impact immune parameters (example -\n             systemic steroids, beta blockers, antidepressants, anti-anxiety drugs, Echinacea\n             supplements, ginseng supplements or Spirulina supplements).\n\n        Exclusion Criteria:\n\n          -  Inability to comprehend and speak English;\n\n          -  Any history of major psychological or psychiatric illness (example - dementia,\n             psychotic disorder, acute mania, current substance abuse) that may limit participant\n             cooperation or compromise the integrity of self-reported clinical or psychological\n             data;\n\n          -  Presence of a confounding underlying systemic illness which could interfere with\n             immunological profiles (example - severe cardiovascular, pulmonary, hepatic,\n             gastrointestinal, renal, neurological, musculoskeletal endocrine , or metabolic\n             systems; other gross physical impairments; or any history of significant convulsive\n             disorder).  Specifically, patients with congestive heart failure, recent viral or\n             bacterial illness in the past 3 weeks, chronic kidney disease, thyroid disorder,\n             autoimmune disease will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784692", 
            "org_study_id": "2012-0255"
        }, 
        "intervention": {
            "arm_group_label": [
                "Immulina 200 mg/day", 
                "Immulina 400 mg/day", 
                "Immulina 800 mg/day"
            ], 
            "intervention_name": "Immulina", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Spirulina"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immulina", 
            "Elderly", 
            "Immune"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "ddmontgomery@umc.edu", 
                "last_name": "Denise D. Montgomery, MT(ASCP)", 
                "phone": "601-815-5374"
            }, 
            "facility": {
                "address": {
                    "city": "Jackson", 
                    "country": "United States", 
                    "state": "Mississippi", 
                    "zip": "39216"
                }, 
                "name": "University of Mississippi Medical Center"
            }, 
            "investigator": {
                "last_name": "Gailen D. Marshall, Jr., MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals", 
        "overall_contact": {
            "email": "ddmontgomery@umc.edu", 
            "last_name": "Denise D. Montgomery, MT(ASCP)", 
            "phone": "601-815-5374"
        }, 
        "overall_official": {
            "affiliation": "University of Mississippi Medical Center", 
            "last_name": "Gailen D. Marshall, Jr., MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Increase in IFNg from baseline to 8 weeks", 
            "measure": "Interferon gamma (IFNg)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784692"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Mississippi Medical Center", 
            "investigator_full_name": "Gailen D. Marshall", 
            "investigator_title": "Professor of Medicine and Pediatrics, Vice Chair for Research, Department of Medicine, Director, Division of Clinical Immunology and Allergy, Chief, Laboratory of Behavioral Immunology Research", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Effects of Immulina on immune biomarkers based upon psychological differences including perceived stress, anxiety, depression and worry", 
                "measure": "Psychological Measures", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Optimizing Immulina dose for maximal immune biomarker levels observing changes in Treg, Tr1, Th3, T Helper1, T Helper 2 cells, salivary cortisol, salivary alpha amylase, Interleukin 4 and Interleukin 10 cytokine production from baseline to 8 weeks", 
                "measure": "Optimal supplement regime", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Effects of Immulina based upon demographic differences including gender, race, age, BMI and socioeconomic status", 
                "measure": "Demographic differences", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Changes in Treg, Tr1, Th3, T Helper 1, T Helper 2 cells, salivary cortisol, salivary alpha amylase, Interleukin 4 and Interleukin 10 cytokine production from baseline to 8 weeks", 
                "measure": "Immune biomarkers", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "University of Mississippi Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Mississippi Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}